AMYE TEVAARWERK, M.D.
Medical Oncology Physician · ROCHESTER, MN
Individual Active NPI 1306879028
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 414 | 81,871 | $6,823,820 | $2,243,903 | $1,786,639 |
| 2023 | 362 | 56,335 | $4,993,833 | $1,601,270 | $1,274,947 |
| 2022 | 254 | 32,835 | $2,658,655 | $871,630 | $694,182 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 10,400 | $51 | $40 |
| J1453 | Injection, fosaprepitant, 1 mg | 9,300 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 7,564 | $49 | $39 |
| J9267 | Injection, paclitaxel, 1 mg | 7,248 | $0 | $0 |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 1,320 | $4 | $3 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,168 | $0 | $0 |
| J9041 | Injection, bortezomib, 0.1 mg | 1,110 | $2 | $1 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 880 | $1 | $1 |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 870 | $33 | $27 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 802 | $0 | $0 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 794 | $0 | $0 |
| 96375 | Injection of additional new drug or substance into vein | 387 | $16 | $13 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | 70385 | MN |
| Medical Oncology Physician | 207RX0202X | 49599 | WI |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Minnesota
- NPI 1437278959
- NPI 1003376468
- NPI 1982680583
- NPI 1801877501
- NPI 1437136553
- NPI 1417148180
- NPI 1265729834
- NPI 1609883321
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.